筋痙縮の世界市場レポート 2025年

筋痙縮市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.8％で64億1,000万米ドルに成長します。予測期間の成長は、患者中心の医療開発、流通チャネルの拡大、QOL向上への注力、標的ドラッグデリバリーシステム開発への注力、バイオマーカーの発見などに起因しています。予測期間における主な動向としては、価値に基づく償還モデルの採用、人工知能と機械学習技術の統合、遠隔医療と遠隔モニタリング技術の採用、神経刺激技術、再生医療アプローチなどが挙げられます。

筋骨格系障害の有病率の増加は、筋痙縮市場の成長を後押しすると予想されます。筋骨格系障害は筋肉、骨、関節に影響を及ぼし、しばしば痛み、こわばり、運動制限を引き起こします。これらの障害の増加要因には、人口の高齢化、座りっぱなしのライフスタイル、慢性疾患の罹患率の増加などがあります。筋痙縮の治療は、痛みを軽減し、可動性を高め、合併症を予防し、患者の全体的な生活の質と機能的能力を向上させることを目的としています。例えば、Lancet誌が2023年11月に発表した研究では、2020年には世界で4億9,400万人が筋骨格系障害を経験し、2050年には115％増加すると予測されています。さらに、アムジェン社は2022年5月に、骨粗鬆症による骨折が2018年の190万件から2040年には320万件へと68％増加する見込みであると報告しています。このような筋骨格系障害の有病率の増加が筋痙縮市場を牽引しています。

筋痙縮市場の主なプレーヤーは、多発性硬化症や脊髄損傷などの疾患による筋痙攣を治療するための経口懸濁液の開発に注力しています。経口懸濁液は、経口摂取用に有効成分を分散させた液体医薬品です。例えば、米国の製薬会社ANI Pharmaceuticals社は、2024年4月にバクロフェン経口懸濁液を発表しました。この製品はFleqsuvyのジェネリック医薬品で、多発性硬化症や脊髄損傷などの症状で筋肉を弛緩させることにより筋肉の痙攣を治療するように設計されています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界筋痙縮 PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の筋痙縮市場：成長率分析
• 世界の筋痙縮市場の実績：規模と成長, 2019-2024
• 世界の筋痙縮市場の予測：規模と成長, 2024-2029, 2034F
• 世界筋痙縮総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の筋痙縮市場薬剤の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• バクロフェン
• ボツリヌス毒素
• ジアゼパム
• ダントロレンナトリウム
• その他の薬物
• 世界の筋痙縮市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 筋肉内
• その他のルート
• 世界の筋痙縮市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の筋痙縮市場バクロフェンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口バクロフェン
• 脊髄内バクロフェン（ポンプ）
• 世界の筋痙縮市場ボツリヌス毒素の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ボトックス（ボツリヌス毒素A型）
• ディスポート（ボツリヌス毒素A型）
• ゼオミン（A型ボツリヌス毒素）
• ミオブロック（ボツリヌス毒素B型）
• 世界の筋痙縮市場ジアゼパムの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口ジアゼパム
• 注射用ジアゼパム
• 世界の筋痙縮市場ダントロレンナトリウムの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口ダントロレン
• 注射用ダントロレン
• 世界の筋痙縮市場その他の医薬品の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• チザニジン
• クロニジン
• ガバペンチン
• その他の筋弛緩剤
• 選択的セロトニン再取り込み阻害薬（SSRI）

第7章 地域別・国別分析

• 世界の筋痙縮市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の筋痙縮市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 筋痙縮市場：競合情勢
• 筋痙縮市場：企業プロファイル
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Medtronic plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Teva Pharmaceutical Industries Ltd.
• Boston Scientific Corporation
• Sun Pharmaceutical Industries Ltd.
• Ipsen Pharma
• Hikma Pharmaceuticals plc
• Endo Pharmaceuticals Inc.
• Lupin Pharmaceuticals Inc.
• Amneal Pharmaceuticals Inc.
• Mallinckrodt Pharmaceuticals
• Neurocrine Biosciences Inc.
• Merz Pharmaceuticals GmbH
• Beximco Pharmaceuticals Ltd.
• ANI Pharmaceuticals Inc.
• Taj Pharmaceuticals Limited
• Revance Therapeutics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 筋痙縮市場2029：新たな機会を提供する国
• 筋痙縮市場2029：新たな機会を提供するセグメント
• 筋痙縮市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Muscle spasticity is a condition marked by an abnormal increase in muscle tone or stiffness that can disrupt movement and speech. It typically arises from damage to the brain or spinal cord that affects the control of voluntary muscle movements.

The main types of drugs used to treat muscle spasticity include baclofen, botulinum toxin, diazepam, dantrolene sodium, and others. These drugs can be administered via various routes, such as oral and intramuscular. They are distributed through multiple channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The muscle spasticity market research report is one of a series of new reports from The Business Research Company that provides muscle spasticity market statistics, including the muscle spasticity industry global market size, regional shares, competitors with muscle spasticity market share, detailed muscle spasticity market segments, market trends, and opportunities, and any further data you may need to thrive in the muscle spasticity industry. These muscle spasticity market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The muscle spasticity market size has grown strongly in recent years. It will grow from $4.19 billion in 2024 to $4.57 billion in 2025 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to increasing investments in research and development, expansion of clinical indications, favorable regulatory approvals and reimbursement policies, increasing emphasis on adopting a multimodal approach, and increasing prevalence of multiple sclerosis.

The muscle spasticity market size is expected to see strong growth in the next few years. It will grow to $6.41 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to growing focus on developing patient-centric care, expansion of distribution channels, focus on improving quality of life, focus on developing targeted drug delivery systems, and discovery of biomarkers. Major trends in the forecast period include adoption of value-based reimbursement models, integration of artificial intelligence and machine learning technologies, adoption of telehealth and remote monitoring technologies, neurostimulation techniques, and regenerative medicine approaches.

The increasing prevalence of musculoskeletal disorders is expected to boost the growth of the muscle spasticity market. Musculoskeletal disorders affect the muscles, bones, and joints, often leading to pain, stiffness, and restricted movement. Factors contributing to the rise in these disorders include aging populations, sedentary lifestyles, and a higher incidence of chronic conditions. Muscle spasticity treatments aim to reduce pain, enhance mobility, prevent complications, and improve the overall quality of life and functional abilities of patients. For example, a study published by The Lancet in November 2023 estimated that 494 million people worldwide experienced musculoskeletal disorders in 2020, with a projected increase of 115% by 2050. Additionally, Amgen reported in May 2022 that fractures due to osteoporosis are expected to rise by 68%, from 1.9 million in 2018 to 3.2 million by 2040. This growing prevalence of musculoskeletal disorders is driving the muscle spasticity market.

Key players in the muscle spasticity market are focusing on developing oral suspensions to treat muscle spasms caused by conditions such as multiple sclerosis and spinal cord injuries. Oral suspensions are liquid medications with active ingredients dispersed for oral consumption. For instance, ANI Pharmaceuticals, a US-based pharmaceutical company, introduced baclofen oral suspension in April 2024. This product, a generic version of Fleqsuvy, is designed to treat muscle spasms by helping to relax the muscles in conditions such as multiple sclerosis and spinal cord injuries.

In January 2022, Amneal Pharmaceuticals Inc., a US-based pharmaceutical manufacturer, acquired the baclofen franchise from Saol Therapeutics, including products such as Lioresal and Lyvispah. This $83.5 million acquisition aims to strengthen Amneal Pharmaceuticals' neurology portfolio and enhance its presence in the institutional market. It also supports Amneal's entry into the biosimilar market, with expected revenue growth from the baclofen franchise by 2025. Saol Therapeutics is a US-based company specializing in developing treatments for limb spasticity and pain related to knee osteoarthritis.

Major companies operating in the muscle spasticity market are F. Hoffmann-La Roche AG, AbbVie Inc., Abbott Laboratories, Novartis AG, Medtronic plc, Teva Pharmaceutical Industries Ltd., Boston Scientific Corporation, Sun Pharmaceutical Industries Ltd., Ipsen Pharma, Hikma Pharmaceuticals plc, Endo Pharmaceuticals Inc., Lupin Pharmaceuticals Inc., Amneal Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Neurocrine Biosciences Inc., Merz Pharmaceuticals GmbH, Beximco Pharmaceuticals Ltd., ANI Pharmaceuticals Inc., Taj Pharmaceuticals Limited, Revance Therapeutics Inc., Acorda Therapeutics Inc., Mylan N.V., Camber Pharmaceuticals Inc., Saol Therapeutics Inc., Zydus Cadila

North America was the largest region in the muscle spasticity market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the muscle spasticity market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the muscle spasticity market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The muscle spasticity market consists of revenues earned by entities by providing services such as pharmaceutical treatments, physical therapy, and occupational therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The muscle spasticity market also includes sales of tizanidine, gabapentin, and pregabalin. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Muscle Spasticity Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on muscle spasticity market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for muscle spasticity ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The muscle spasticity market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Baclofen; Botulinum Toxin; Diazepam; Dantrolene Sodium; Other Drugs
• 2) By Route Of Administration: Oral; Intramuscular; Other Routes
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Baclofen: Oral Baclofen; Intrathecal Baclofen (Pump)
• 2) By Botulinum Toxin: Botox (Botulinum Toxin Type A); Dysport (Botulinum Toxin Type A); Xeomin (Botulinum Toxin Type A); Myobloc (Botulinum Toxin Type B)
• 3) By Diazepam: Oral Diazepam; Injectable Diazepam
• 4) By Dantrolene Sodium: Oral Dantrolene; Injectable Dantrolene
• 5) By Other Drugs: Tizanidine; Clonidine; Gabapentin; Other Muscle Relaxants; Selective Serotonin Reuptake Inhibitors (SSRIs)
• Companies Mentioned: F. Hoffmann-La Roche AG; AbbVie Inc.; Abbott Laboratories; Novartis AG; Medtronic plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Muscle Spasticity Market Characteristics

3. Muscle Spasticity Market Trends And Strategies

4. Muscle Spasticity Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Muscle Spasticity Growth Analysis And Strategic Analysis Framework

• 5.1. Global Muscle Spasticity PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Muscle Spasticity Market Growth Rate Analysis
• 5.4. Global Muscle Spasticity Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Muscle Spasticity Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Muscle Spasticity Total Addressable Market (TAM)

6. Muscle Spasticity Market Segmentation

• 6.1. Global Muscle Spasticity Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Baclofen
• Botulinum Toxin
• Diazepam
• Dantrolene Sodium
• Other Drugs
• 6.2. Global Muscle Spasticity Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intramuscular
• Other Routes
• 6.3. Global Muscle Spasticity Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.4. Global Muscle Spasticity Market, Sub-Segmentation Of Baclofen, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Baclofen
• Intrathecal Baclofen (Pump)
• 6.5. Global Muscle Spasticity Market, Sub-Segmentation Of Botulinum Toxin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Botox (Botulinum Toxin Type A)
• Dysport (Botulinum Toxin Type A)
• Xeomin (Botulinum Toxin Type A)
• Myobloc (Botulinum Toxin Type B)
• 6.6. Global Muscle Spasticity Market, Sub-Segmentation Of Diazepam, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Diazepam
• Injectable Diazepam
• 6.7. Global Muscle Spasticity Market, Sub-Segmentation Of Dantrolene Sodium, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Dantrolene
• Injectable Dantrolene
• 6.8. Global Muscle Spasticity Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tizanidine
• Clonidine
• Gabapentin
• Other Muscle Relaxants
• Selective Serotonin Reuptake Inhibitors (SSRIs)

7. Muscle Spasticity Market Regional And Country Analysis

• 7.1. Global Muscle Spasticity Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Muscle Spasticity Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Muscle Spasticity Market

• 8.1. Asia-Pacific Muscle Spasticity Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Muscle Spasticity Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Muscle Spasticity Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Muscle Spasticity Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Muscle Spasticity Market

• 9.1. China Muscle Spasticity Market Overview
• 9.2. China Muscle Spasticity Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Muscle Spasticity Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Muscle Spasticity Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Muscle Spasticity Market

• 10.1. India Muscle Spasticity Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Muscle Spasticity Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Muscle Spasticity Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Muscle Spasticity Market

• 11.1. Japan Muscle Spasticity Market Overview
• 11.2. Japan Muscle Spasticity Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Muscle Spasticity Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Muscle Spasticity Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Muscle Spasticity Market

• 12.1. Australia Muscle Spasticity Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Muscle Spasticity Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Muscle Spasticity Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Muscle Spasticity Market

• 13.1. Indonesia Muscle Spasticity Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Muscle Spasticity Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Muscle Spasticity Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Muscle Spasticity Market

• 14.1. South Korea Muscle Spasticity Market Overview
• 14.2. South Korea Muscle Spasticity Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Muscle Spasticity Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Muscle Spasticity Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Muscle Spasticity Market

• 15.1. Western Europe Muscle Spasticity Market Overview
• 15.2. Western Europe Muscle Spasticity Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Muscle Spasticity Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Muscle Spasticity Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Muscle Spasticity Market

• 16.1. UK Muscle Spasticity Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Muscle Spasticity Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Muscle Spasticity Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Muscle Spasticity Market

• 17.1. Germany Muscle Spasticity Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Muscle Spasticity Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Muscle Spasticity Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Muscle Spasticity Market

• 18.1. France Muscle Spasticity Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Muscle Spasticity Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Muscle Spasticity Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Muscle Spasticity Market

• 19.1. Italy Muscle Spasticity Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Muscle Spasticity Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Muscle Spasticity Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Muscle Spasticity Market

• 20.1. Spain Muscle Spasticity Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Muscle Spasticity Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Muscle Spasticity Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Muscle Spasticity Market

• 21.1. Eastern Europe Muscle Spasticity Market Overview
• 21.2. Eastern Europe Muscle Spasticity Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Muscle Spasticity Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Muscle Spasticity Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Muscle Spasticity Market

• 22.1. Russia Muscle Spasticity Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Muscle Spasticity Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Muscle Spasticity Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Muscle Spasticity Market

• 23.1. North America Muscle Spasticity Market Overview
• 23.2. North America Muscle Spasticity Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Muscle Spasticity Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Muscle Spasticity Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Muscle Spasticity Market

• 24.1. USA Muscle Spasticity Market Overview
• 24.2. USA Muscle Spasticity Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Muscle Spasticity Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Muscle Spasticity Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Muscle Spasticity Market

• 25.1. Canada Muscle Spasticity Market Overview
• 25.2. Canada Muscle Spasticity Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Muscle Spasticity Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Muscle Spasticity Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Muscle Spasticity Market

• 26.1. South America Muscle Spasticity Market Overview
• 26.2. South America Muscle Spasticity Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Muscle Spasticity Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Muscle Spasticity Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Muscle Spasticity Market

• 27.1. Brazil Muscle Spasticity Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Muscle Spasticity Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Muscle Spasticity Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Muscle Spasticity Market

• 28.1. Middle East Muscle Spasticity Market Overview
• 28.2. Middle East Muscle Spasticity Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Muscle Spasticity Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Muscle Spasticity Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Muscle Spasticity Market

• 29.1. Africa Muscle Spasticity Market Overview
• 29.2. Africa Muscle Spasticity Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Muscle Spasticity Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Muscle Spasticity Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Muscle Spasticity Market Competitive Landscape And Company Profiles

• 30.1. Muscle Spasticity Market Competitive Landscape
• 30.2. Muscle Spasticity Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Medtronic plc Overview, Products and Services, Strategy and Financial Analysis

31. Muscle Spasticity Market Other Major And Innovative Companies

• 31.1. Teva Pharmaceutical Industries Ltd.
• 31.2. Boston Scientific Corporation
• 31.3. Sun Pharmaceutical Industries Ltd.
• 31.4. Ipsen Pharma
• 31.5. Hikma Pharmaceuticals plc
• 31.6. Endo Pharmaceuticals Inc.
• 31.7. Lupin Pharmaceuticals Inc.
• 31.8. Amneal Pharmaceuticals Inc.
• 31.9. Mallinckrodt Pharmaceuticals
• 31.10. Neurocrine Biosciences Inc.
• 31.11. Merz Pharmaceuticals GmbH
• 31.12. Beximco Pharmaceuticals Ltd.
• 31.13. ANI Pharmaceuticals Inc.
• 31.14. Taj Pharmaceuticals Limited
• 31.15. Revance Therapeutics Inc.

32. Global Muscle Spasticity Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Muscle Spasticity Market

34. Recent Developments In The Muscle Spasticity Market

35. Muscle Spasticity Market High Potential Countries, Segments and Strategies

• 35.1 Muscle Spasticity Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Muscle Spasticity Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Muscle Spasticity Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer